Kush Parmar Sells 52,317 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 52,317 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $6.85, for a total transaction of $358,371.45. Following the completion of the sale, the director directly owned 2,783,781 shares of the company’s stock, valued at $19,068,899.85. This trade represents a 1.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Kush Parmar also recently made the following trade(s):

• On Monday, August 10th, Kush Parmar sold 92,444 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.00, for a total transaction of $647,108.00.
• On Thursday, August 6th, Kush Parmar sold 10,494 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.00, for a total transaction of $73,458.00.
• On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.85, for a total transaction of $11,768.30.
• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.93, for a total transaction of $795,259.08.

Entrada Therapeutics Trading Up 1.3%

Shares of NASDAQ:TRDA opened at $7.04 on Wednesday. The stock’s 50-day moving average price is $6.87 and its 200-day moving average price is $9.65. Entrada Therapeutics, Inc. has a 12-month low of $5.02 and a 12-month high of $16.45. The stock has a market capitalization of $274.14 million, a P/E ratio of -1.78 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. As a group, research analysts predict that Entrada Therapeutics, Inc. will post -4.07 EPS for the current year.

Hedge Funds Weigh In On Entrada Therapeutics

Several hedge funds have recently made changes to their positions in TRDA. Baker BROS. Advisors LP boosted its holdings in Entrada Therapeutics by 4.3% in the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after acquiring an additional 206,911 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Entrada Therapeutics by 735.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 133,878 shares of the company’s stock valued at $776,000 after purchasing an additional 117,844 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Entrada Therapeutics by 9.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after buying an additional 1,560 shares during the period. Great Lakes Advisors LLC purchased a new position in shares of Entrada Therapeutics during the second quarter valued at about $283,000. Finally, BlackRock Inc. bought a new position in Entrada Therapeutics in the second quarter worth about $19,013,000. 86.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TRDA shares. Roth Capital set a $10.00 target price on shares of Entrada Therapeutics in a report on Friday, May 8th. Guggenheim dropped their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. HC Wainwright cut shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $17.50.

Entrada Therapeutics News Roundup

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock opened a position worth about $19.0 million, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These purchases may provide some underlying demand for TRDA shares.
• Positive Sentiment: Analyst coverage remains mixed but includes three Buy ratings. The average price target is reported at $17.50, well above recent trading levels, although HC Wainwright downgraded the stock to Neutral and Guggenheim lowered its target to $17.00. Entrada Therapeutics analyst and stock information
• Neutral Sentiment: Reported short interest was zero shares, with a zero-day days-to-cover ratio. Because the data also shows an “NaN” change from the prior period, it offers little reliable insight into current short-selling pressure.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold a combined 62,811 shares on August 6 and 7 for approximately $431,829, reducing its position by about 2.2%. The shareholder still owns more than 2.7 million shares, so the sales represent a modest reduction rather than a full exit. SEC filing on Ventures V. L.P. 5Am share sales
• Negative Sentiment: Director Kush Parmar sold 155,255 shares across three transactions from August 6 through August 10 for roughly $1.08 million, cutting his holdings by approximately 5.5%. Repeated insider selling can weigh on sentiment, even though he continues to hold a substantial stake. SEC filing on Kush Parmar share sales
• Negative Sentiment: Entrada’s latest quarterly results missed expectations: adjusted loss per share was $1.01 versus an expected $0.97 loss, while revenue of $0.90 million fell short of the $2.32 million consensus. The clinical-stage biotechnology company is expected to remain unprofitable, with analysts forecasting a full-year loss of approximately $4.07 per share.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.